Aeglea BioTherapeutics Inc (AGLE)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014305
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company’s product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in the blood. Aeglea BioTherapeutics is developing products for the treatment of Arginase I Deficiency; homocystinuria and others. The company works in partnership with research institutions, allied healthcare providers and pharmaceutical companies to discover, develop and market new product candidates. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc (AGLE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Venture Financing 12
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Partnerships 16
Aeglea BioTherapeutics Enters into Agreement with Merck 16
Licensing Agreements 17
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
AECase Enters into Licensing Agreement with University of Texas at Austin 18
Equity Offering 19
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 19
Aeglea BioTherapeutics Raises USD54.8 million in IPO 20
Aeglea BioTherapeutics Inc – Key Competitors 21
Aeglea BioTherapeutics Inc – Key Employees 22
Aeglea BioTherapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Nov 07, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 24
Aug 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 25
May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 26
Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 27
Nov 09, 2016: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 29
Aug 09, 2016: Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results 31
May 19, 2016: Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results 33
Corporate Communications 34
Jul 20, 2017: Aeglea BioTherapeutics Announces Leadership Change 34
Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 35
Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 36
May 16, 2016: Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer 37
Mar 15, 2016: Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of Directors 38
Product News 39
11/08/2016: Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors 39
Product Approvals 40
May 23, 2016: Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency 40
Mar 14, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies 41
Jan 07, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of Its Investigational New Drug Application for AEB1102 for the Treatment of Arginase I Deficiency 42
Clinical Trials 43
Sep 15, 2016: Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency 43
Aug 29, 2016: Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies 44
Jul 18, 2016: Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer 45
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Aeglea BioTherapeutics Enters into Agreement with Merck 16
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
AECase Enters into Licensing Agreement with University of Texas at Austin 18
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 19
Aeglea BioTherapeutics Raises USD54.8 million in IPO 20
Aeglea BioTherapeutics Inc, Key Competitors 21
Aeglea BioTherapeutics Inc, Key Employees 22
Aeglea BioTherapeutics Inc, Subsidiaries 23

★海外企業調査レポート[Aeglea BioTherapeutics Inc (AGLE)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fox Corp (FOXA):企業の財務・戦略的SWOT分析
    Fox Corp (FOXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Citizens Electric Corporation:企業の発電所・SWOT分析2018
    Citizens Electric Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Exelixis Inc (EXEL):企業の財務・戦略的SWOT分析
    Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Chiyoda Corporation (6366)-石油・ガス分野:企業M&A・提携分析
    Summary Chiyoda Corporation (Chiyoda) is an engineering services provider that offers various services along with its subsidiaries. Its offerings include project management, program management, feasibility studies, front end engineering design works, engineering, procurement, construction, commissio …
  • Marvel Entertainment LLC:企業の戦略的SWOT分析
    Marvel Entertainment LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Raiffeisen Bank International AG:企業の戦略・SWOT・財務情報
    Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report Summary Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Clean Harbors Inc (CLH):石油・ガス:M&Aディール及び事業提携情報
    Summary Clean Harbors Inc (Clean Harbors) is a provider of environmental, industrial and energy services. The company offers waste disposal and recycling, emergency response, chemical packing, field services, production services, exploration services, directional boring, lodging services and onsite …
  • Barnwell Industries Inc (BRN):石油・ガス:M&Aディール及び事業提携情報
    Summary Barnwell Industries Inc (Barnwell) is a diversified company. The company's business activities include oil and natural gas, land investment, and contract drilling. Its oil and natural gas division offers exploration, development, production, and sales of oil and natural gas in Canada. Barnwe …
  • Future Plc (FUTR):企業の財務・戦略的SWOT分析
    Summary Future Plc (Future) is a media company that offers media and digital business solutions various customers. The company offers its services in various areas such as technology, photography, creative and design, games, advertising and film and music. It provides licensing and syndication, expo …
  • NCC Group PLC (NCC):企業の財務・戦略的SWOT分析
    NCC Group PLC (NCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Praxair Inc (PX):石油・ガス:M&Aディール及び事業提携情報
    Summary Praxair Inc (Praxair) is a producer and supplier of industrial gases. The company produces atmospheric gases including oxygen, nitrogen, argon and rare gases, and process gases such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases and acetylene. It also designs and buil …
  • Omega Pharma NV:企業のM&A・事業提携・投資動向
    Omega Pharma NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Omega Pharma NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Lantronix, Inc. (LTRX):企業の財務・戦略的SWOT分析
    Lantronix, Inc. (LTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Rohto Pharmaceutical Co Ltd (4527):企業の財務・戦略的SWOT分析
    Summary Rohto Pharmaceutical Co Ltd (Rohto Pharmaceutical) is a pharmaceutical company that manufactures and markets cosmetics and functional foods. The company offers products such as eye care products, skin care products, oral medicine product, cosmetics, eye drops, gastrointestinal medicines, der …
  • Fulgent Genetics Inc (FLGT):企業の財務・戦略的SWOT分析
    Fulgent Genetics Inc (FLGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Syndax Pharmaceuticals Inc (SNDX):医療機器:M&Aディール及び事業提携情報
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • FirstRand Ltd (FSR):企業の財務・戦略的SWOT分析
    FirstRand Ltd (FSR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • ESI Group S.A. (ESI):企業の財務・戦略的SWOT分析
    ESI Group S.A. (ESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SARIA AS GmbH & Co KG:企業の戦略的SWOT分析
    SARIA AS GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Exelon Corporation (EXC):電力:M&Aディール及び事業提携情報
    Summary Exelon Corporation (Exelon) is a utility services holding company operating across the energy value chain comprising power generation, distribution, transmission and energy sales. It generates electricity from diverse sources, including nuclear, fossil fuels and renewable energy. Exelon deli …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆